bioTheranostics’ New Biot3 Metastatic Cancer Solution Provides Comprehensive Genomic Testing With Integration Of Next Generation Sequencing

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--bioTheranostics, Inc., today introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provide personalized diagnostic information and therapeutic guidance for metastatic cancer patients across the continuum of care.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC